Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -7 of 7 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Phase 2 Study in Patients With MiT Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				13 and over				Pharmaceutical / Industry				ARQ 197-204 NCT00557609


2.		A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				ARQ 197-209 NCT00777309


3.		ARQ 197 in Subjects With Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Tissue collection/Repository				Active				18 and over				Pharmaceutical / Industry				ARQ 197-101 NCT00302172


4.		A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				20 and over				Pharmaceutical / Industry				ARQ 197-0701 NCT00609921


5.		A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				ARQ 197-103 NCT00612209


6.		A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				ARQ 197-111 NCT00612703


7.		Safety Study of ARQ 197 in Cirrhotic Patients With Carcinoma (HCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				ARQ 197-114 NCT00802555

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute